MYNZ Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

--

Open

--

VWAP

--

Vol

--

Mkt Cap

10.20M

Low

--

Amount

--

EV/EBITDA(TTM)

--

Total Shares

--

EV

7.69M

EV/OCF(TTM)

--

P/S(TTM)

2.89

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

Show More

Events Timeline

(ET)

2026-03-13

07:40:00

Mainz Biomed Renames to Quantum Cyber, Changes Ticker to QUCY

2026-03-11 (ET)

2026-03-11

07:40:00

Mainz Biomed Appoints Robert Liscouski as Chairman and Renames to Quantum Cyber

2026-02-17 (ET)

2026-02-17

07:40:00

Mainz Biomed Signs $6M Financing Agreement

2026-01-05 (ET)

2026-01-05

09:20:00

Mainz Biomed Reviews 2025 Achievements and Future Outlook

2025-12-05 (ET)

2025-12-05

17:10:00

Mainz Biomed Files $150M Mixed Securities Shelf

2025-12-02 (ET)

2025-12-02

08:31:00

Mainz Biomed Adds ColoAlert Test to DoctorBox Portfolio

2025-11-18 (ET)

2025-11-18

09:29:29

Mainz Biomed and OncoVanguard8 Partner to Introduce ColoAlert in South America

2025-10-08 (ET)

2025-10-08

09:03:11

Mainz Biomed announces findings from biomarker panel feasibility study

News

Newsfilter

02-24Newsfilter

Mainz Biomed to Present at Digestive Disease Week 2026

seekingalpha

02-17seekingalpha

Mainz Biomed Secures $6 Million Financing for Strategic Shift

Newsfilter

02-17Newsfilter

Mainz Biomed Secures $6 Million Funding to Enhance Liquidity and Focus on Pancreatic Cancer Detection

Globenewswire

01-05Globenewswire

Mainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients

Globenewswire

2025-12-02Globenewswire

Mainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany

Newsfilter

2025-12-02Newsfilter

Mainz Biomed Partners with DoctorBox to Launch ColoAlert Test in Germany

1 Analyst Rating

Wall Street analysts forecast MYNZ stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

14.00

Averages

14.00

High

14.00

Current: 0.000

Low

14.00

Averages

14.00

High

14.00

Maxim

Buy

to

Hold

downgrade

AI Analysis

2026-03-06

Reason

Maxim

Price Target

AI Analysis

2026-03-06

downgrade

Buy

to

Hold

Reason

Maxim downgraded Mainz Biomed to Hold from Buy.

Maxim

Buy -> Hold

downgrade

2026-03-06

Reason

Maxim

Price Target

2026-03-06

downgrade

Buy -> Hold

Reason

As previously reported, Maxim downgraded Mainz Biomed to Hold from Buy. The firm is citing the company's plans to terminate development of its colorectal cancer platform and focus on its pancreatic cancer diagnostic, which recently reported sensitivity of 100% at a 95% specificity in its recent feasibility study, the analyst tells investors in a research note. Maxim further notes the significant dilution from a change in Mainz capital structure and timeline uncertainty associated with a shift in business strategy.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MYNZ

Unlock Now

Valuation Metrics

The current forward P/E ratio for Mainz Biomed NV (MYNZ.O) is -0.55, compared to its 5-year average forward P/E of -2.52. For a more detailed relative valuation and DCF analysis to assess Mainz Biomed NV's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.52

Current PE

-0.55

Overvalued PE

0.10

Undervalued PE

-5.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

54.54

Current PS

10.62

Overvalued PS

133.95

Undervalued PS

-24.87

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Qué acciones tienen el rsi por debajo de 30

Intellectia · 288 candidates

Region: USRsi Category: oversoldList Exchange: XNYS, XNAS, XASE

Ticker

Name

Market Cap$

Similarweb Ltd

336.50M

Strata Skin Sciences Inc

1.86M

urban-gro Inc

2.43M

Goosehead Insurance Inc

1.87B

Ensysce Biosciences Inc

1.58M

Southland Holdings Inc

81.17M

Best stock under 3.50 that will 3x

Intellectia · 29 candidates

Market Cap: <= 2.00BPrice: <= $3.50Beta: HighRiskRevenue 5yr Cagr: >= 20Annual Eps Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

Clarivate PLC

1.86B

Bitfarms Ltd

1.61B

Blend Labs Inc

732.49M

SNDL Inc

406.85M

Lineage Cell Therapeutics Inc

382.34M

SelectQuote Inc

283.31M

Whales Holding MYNZ

Trading Trends

People Also Watch

Frequently Asked Questions

What is Mainz Biomed NV (MYNZ) stock price today?

The current price of MYNZ is 0 USD — it has increased 2.01

What is Mainz Biomed NV (MYNZ)'s business?

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.

What is the price predicton of MYNZ Stock?

Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Mainz Biomed NV (MYNZ)'s revenue for the last quarter?

Mainz Biomed NV revenue for the last quarter amounts to 214.76K USD, decreased

What is Mainz Biomed NV (MYNZ)'s earnings per share (EPS) for the last quarter?

Mainz Biomed NV. EPS for the last quarter amounts to -0.27 USD, decreased

How many employees does Mainz Biomed NV (MYNZ). have?

Mainz Biomed NV (MYNZ) has 19 emplpoyees as of March 22 2026.

What is Mainz Biomed NV (MYNZ) market cap?

Today MYNZ has the market capitalization of 10.20M USD.